Compare IDN & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDN | KLRS |
|---|---|---|
| Founded | 1994 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.4M | 44.5M |
| IPO Year | 2014 | 2020 |
| Metric | IDN | KLRS |
|---|---|---|
| Price | $2.02 | $2.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | $4.83 | ★ $17.67 |
| AVG Volume (30 Days) | ★ 238.8K | 58.1K |
| Earning Date | 11-12-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 220.00 | 75.70 |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $4,433,454.00 | $165,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $34.83 | ★ N/A |
| Revenue Growth | ★ 23.21 | N/A |
| 52 Week Low | $2.07 | $1.78 |
| 52 Week High | $9.08 | $11.88 |
| Indicator | IDN | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 30.61 | 56.30 |
| Support Level | N/A | N/A |
| Resistance Level | $2.49 | $4.37 |
| Average True Range (ATR) | 0.15 | 0.18 |
| MACD | -0.03 | 0.10 |
| Stochastic Oscillator | 8.73 | 79.55 |
Intellicheck Inc is a trusted industry leader in technology solutions that stop identity theft and fraud with real-time identification authentication and age verification. The group delivers on-demand digital and physical identity verification solutions for KYC, AML, fraud prevention, and age verification needs. The products of the company includes solutions for preventing identity fraud across any industry delivered via smartphone, tablet, POS integration or other electronic devices.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.